(Bloomberg) — A US judge in Florida for now tossed out President Donald Trump’s $15 billion defamation lawsuit against the New York Times days after it was filed, finding the president’s lawyers failed to follow court rules requiring “short, plain, direct” claims. Most Read from Bloomberg US District Judge Steven Merryday issued an order on Friday concluding that Trump’s lawsuit “unmistakably and inexcusably” violated the court’s rules by featuring “repetitive,” “superfluous” and “florid” allegations and ...

A Florida judge on Friday temporarily dismissed U.S. President Donald Trump's $15B lawsuit against The New York Times (NYSE:NYT) for being too long and violating court rules. According to U.S. District Judge Steven Merryday, Trump's lawyers did not follow the court rules ...

Core Points - A U.S. judge dismissed former President Trump's $1.5 billion lawsuit against The New York Times, allowing him to amend his complaint [1] - The judge ruled that Trump's lawsuit violated federal rules and required a concise statement to justify the claim for damages [1] - The judge emphasized that the lawsuit is not a platform for personal attacks or a public forum for insults [1] Summary by Sections Legal Proceedings - The court documents revealed that the lawsuit filed by Trump was rejected by the judge, who stated that it did not meet the necessary legal standards [1] - Trump had announced the lawsuit on September 15 via his social media platform, claiming defamation by The New York Times [1] Responses - The New York Times responded to Trump's lawsuit, asserting that it lacks legal merit and characterizing it as an attempt to suppress independent reporting [1]

Core Points - A federal judge dismissed Donald Trump's $15 billion lawsuit against The New York Times, stating the complaint was "improper and impermissible" [1][2] - The judge allowed Trump's legal team to file a new complaint within 28 days, with a maximum length of 48 pages [1] - The lawsuit accused The New York Times of being a "mouthpiece of the Democrat party" and claimed it misrepresented Trump's rise to fame [3] Legal Proceedings - Judge Steven Merryday emphasized that the complaint did not adhere to the requirements of Rule 8, which governs the format and content of legal complaints [2][4] - The judge criticized the complaint for being more of a public relations statement rather than a formal legal document, stating it should inform defendants in a professional manner [4] Trump's Position - Trump's lawsuit included grievances against specific articles and authors, claiming they falsely portrayed his celebrity status as being created by the show "The Apprentice" [3] - A spokesperson for Trump's legal team indicated that the lawsuit aims to hold the media accountable and will continue despite the judge's ruling [4] The New York Times' Response - The New York Times responded to the lawsuit by asserting that it lacks merit and is an attempt to suppress independent journalism [4]

A federal judge on Friday struck Donald Trump's $15 billion defamation lawsuit against the New York Times over its content. ...

Core Insights - OS Therapies has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics" Spotlight Panel at BioFuture 2025, highlighting its focus on innovative cancer treatments [1][3] - The company plans to submit a Biologics Licensing Application (BLA) to the FDA in Q4 2025, aiming for approval that could lead to a Priority Review Voucher (PRV) sale to fund further clinical development [2][4] - OS Therapies' lead asset, OST-HER2, is an immunotherapy targeting HER2 protein, showing promising results in clinical trials for osteosarcoma and breast cancer [4][5] Company Overview - OS Therapies is a clinical-stage oncology company focused on developing treatments for osteosarcoma and other solid tumors, leveraging a unique listeria monocytogenes platform technology [3][4] - The company has received multiple designations from the FDA, including Rare Pediatric Disease Designation and Fast-Track status for OST-HER2, which has shown statistically significant benefits in clinical trials [4] - OS Therapies is also advancing next-generation Antibody Drug Conjugates (ADCs) and Drug Conjugates (DCs) through its proprietary technology [5][6]

Group 1 - The core focus of Crude Value Insights is on cash flow and companies that generate it, highlighting value and growth prospects in the oil and natural gas sector [1] - Subscribers benefit from a 50+ stock model account, which provides a comprehensive overview of investment opportunities [1] - The service includes in-depth cash flow analyses of exploration and production (E&P) firms, enhancing understanding of the sector's financial health [1] Group 2 - The platform offers a live chat discussion feature, fostering community engagement and real-time information sharing among subscribers [1]

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating (FSR) of C++ (Marginal) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "b+†(Marginal) of Genworth Life Insurance Company (GLIC) (Wilmington, DE) and Genworth Life Insurance Company of New York (GLICNY) (New York, NY). These companies are referred to as Genworth Financial Group. In addition, AM Best has affirmed the FSR of B- (Fair) and the Long- Term IC ...

President Donald Trump's latest move against media companies is a $15 billion lawsuit against the New York Times alleging defamation. It has one important difference from another high-profile suit by ... ...

Market Overview - The major indices showed mixed results, with the Dow Jones Industrial Average (DJIA) gaining 0.1% to close at 45,883.45 points, the S&P 500 (SPX) rising 0.5% to an all-time high of 6,615.28 points, and the Nasdaq Composite (IXIC) climbing 0.9% to a record close of 22,348.75 points [2] - The S&P 500's advance of 10.32% during the first 164 sessions of Trump's second term is nearly identical to the 10.37% rise during the same period in his first term [2] TikTok Deal - A deal was announced to keep TikTok operating in the U.S., involving the transfer of its U.S. assets from ByteDance to American owners, which President Trump described as an "upgrade for both countries" [3] - Oracle (ORCL) shares surged as much as 5% in premarket trading following news of its likely involvement in the TikTok deal, with shares up more than 3% by Tuesday morning [4] - The deal is expected to close within 30 to 45 days and could signify a breakthrough in the U.S.-China trade war [4] Legal Actions - President Trump filed a $15 billion defamation lawsuit against The New York Times (NYT), claiming a "decades-long pattern" of defamation against him and his movement [5] - Following the lawsuit announcement, shares of The New York Times Company fell 2.4% [6] - This lawsuit marks the fourth multibillion-dollar legal action Trump has taken against media companies since returning to office [6] Corporate Reporting Changes - President Trump proposed shifting U.S. corporate reporting from quarterly to semi-annual, arguing it would save money and allow better management focus [7] - Analysts predict a 60% chance that this shift could become a reality, indicating a potential reversal of decades-old SEC policy [7] Tariff Policies - President Trump has threatened to impose tariffs of 50-100% on Chinese goods as part of his foreign policy strategy [8] - U.S. Treasury Secretary indicated that new tariffs on Chinese goods related to Russian oil purchases would be held off if European countries impose significant duties [8] - The market has shown resilience to tariff announcements, with retail sales rising 0.6% in August despite ongoing inflation concerns [8] Conclusion - The market remains in a state of high-stakes drama influenced by Trump's policies, legal actions, and international trade negotiations, creating a dynamic environment for investors [9]